retatrutide vs semaglutide weight loss comparison Mounjaro vs Ozempic: 2026 Data Is Decisive Lilly orforglipron oral GLP-1 phase

Firstly, an analysis published in Fertility and Sterility found potential improvements in fertility-related outcomes among women with PMOS

Study: TripleHormone Receptor Agonist Retatrutide for Obesity (Phase 2 Trial, NEJM) Drug: Retatrutide a triple agonist (GLP-1, GIP, and glucagon receptors) Key Findings: Up to 28.7% mean weight loss at higher doses Marked improvements in insulin sensitivity and cardiometabolic risk factors Weight loss approaching outcomes seen with bariatric surgery, without surgery What makes Retatrutide unique is its triple-hormone mechanism, simultaneously targeting appetite regulation, energy expenditure, and glucose metabolism

doi: 10.1210/clinem/dgaa891 50 AlanteetAAAttiaHAShaheenSAlfayezMAlshanawaniB

doi: 10.1016/j.ejca.2015.09.027 [DOI] [PubMed] [Google Scholar] 51.Nayan M, Punjani N, Juurlink DN, et al

Rotate injection sites to avoid lipohypertrophy (fat-pad buildup)

Open communication with a trial clinician about tolerability is therefore essential